REGIONAL ANALYSIS OF A COHORT COMPASSIONATE-USE PROGRAM AND EARLY ACCESS PROGRAM WITH CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL

被引：0
|
作者：
Malik, Z. [1 ]
di Lorenzo, G. [2 ]
Bracarda, S. [3 ]
Ardavanis, A. [4 ]
Basaran, M. [5 ]
Parente, P. [6 ]
de Schultz, W. [7 ]
Saad, F. [8 ]
van Oort, I. [9 ]
Gerritsen, W. R. [9 ]
Aparicio, L. M. Anton [10 ]
Matus, G. [11 ]
Hitier, S. [12 ]
Heidenreich, A. [13 ]
Bahl, A. [14 ]
机构：
[1] Clatterbridge Canc Ctr, Bebington, England
[2] Univ Naples Federico II, Naples, Italy
[3] ITT, Arezzo, Italy
[4] St Savas Anticanc Hosp, Athens, Greece
[5] Inst Oncol, Istanbul, Turkey
[6] Monash Univ, Fac Med, Melbourne, Vic 3004, Australia
[7] Urol Clin, Weissenfles, Germany
[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[9] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[10] Hosp Juan Canalejo, La Coruna, Spain
[11] Clin St Joseph, Liege, Belgium
[12] Sanofi, Chilly Mazarin, France
[13] Univ Hosp, Aachen, Germany
[14] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [41] Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer
    Bracarda, Sergio
    Gernone, Angela
    Gasparro, Donatello
    Marchetti, Paolo
    Ronzoni, Monica
    Bortolus, Roberto
    Fratino, Lucia
    Basso, Umberto
    Mazzanti, Roberto
    Messina, Caterina
    Tucci, Marcello
    Boccardo, Francesco
    Carteni, Giacomo
    Pinto, Carmine
    Fornarini, Giuseppe
    Mattioli, Rodolfo
    Procopio, Giuseppe
    Chiuri, Vincenzo
    Scotto, Tiziana
    Dondi, Davide
    Di Lorenzo, Giuseppe
    FUTURE ONCOLOGY, 2014, 10 (06) : 975 - 983
  • [42] Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
    Castellano, Daniel
    Anton Aparicio, Luis M.
    Esteban, Emilio
    Sanchez-Hernandez, Alfredo
    Ramon Germa, Jose
    Batista, Norberto
    Maroto, Pablo
    Perez-Valderrama, Begona
    Luque, Raquel
    Jose Mendez-Vidal, Maria
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (09) : 1165 - 1173
  • [43] COST-UTILITY ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Vicente, C.
    Babashov, V
    Husein, F.
    Saad, F.
    Naidoo, S.
    Holmstrom, S.
    VALUE IN HEALTH, 2014, 17 (03) : A89 - A90
  • [44] Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
    Massard, C.
    Mateo, J.
    Loriot, Y.
    Pezaro, C.
    Albiges, L.
    Mehra, N.
    Varga, A.
    Bianchini, D.
    Ryan, C. J.
    Petrylak, D. P.
    Attard, G.
    Shen, L.
    Fizazi, K.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2017, 28 (01) : 90 - 95
  • [45] Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
    Thibault, Constance
    Eymard, Jean-Christophe
    Hardy-Bessard, Anne-Claire
    Birtle, Alison J.
    Krainer, Michael
    Baciarello, Giulia
    Flechon, Aude
    Le Moulec, Sylvestre
    Spaeth, Dominique
    Laguerre, Brigitte
    Caffo, Orazio
    Deville, Jean-Laurent
    Beuzeboc, Philippe
    Hasbini, Ali
    Gross-Goupil, Marine
    Helissey, Carole
    Bennamoun, Mostefa
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
    Vauchier, C.
    Thibault, C.
    Velev, M.
    Becker, O.
    Oudard, S.
    Auclin, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S990 - S991
  • [47] Safety of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel: Expanded Access in North America
    Joshua, Anthony M.
    Shore, Neal D.
    Saad, Fred
    Chi, Kim N.
    Olsson, Carl A.
    Emmenegger, Urban
    Scholz, Mark
    Berry, William
    Mukherjee, Som D.
    Winquist, Eric
    Haas, Naomi B.
    Foley, Margaret A.
    Dmuchowski, Carl
    Perabo, Frank
    Hirmand, Mohammad
    Hasabou, Nahla
    Rathkopf, Dana
    PROSTATE, 2015, 75 (08): : 836 - 844
  • [48] HEALTH-RELATED QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): CABAZITAXEL EARLY ACCESS PROGRAM (EAP) INTERIM RESULTS FROM CANADA
    Saad, F.
    Winquist, E.
    Girard, M.
    Sridhar, S. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 315 - 315
  • [49] Safety of cabazitaxel in elderly patients with metastatic castrate resistant prostate cancer (mCRPC) previously treated with docetaxel therapy.
    Gernone, Angela
    Calderoni, Giuseppe
    Vallarelli, Simona
    Montagna, Elisa
    Pagliarulo, Arcangelo
    Silvestris, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Use of cabazitaxel in treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): patient characteristics, safety and effectiveness in the FUJI cohort
    Fourrier-Reglat, A.
    Oudard, S.
    Fizazi, K.
    Joly, F.
    Tubach, F.
    Rouyer, M.
    Lamarque, S.
    Guiard, E.
    Balestra, A.
    Lacueille, C.
    Jove, J.
    Droz-Perroteau, C.
    Moore, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 60 - 60
12345